Cangene signs extension for botulism antitoxin contract

A no-cost modification has been signed by Cangene Corporation to extend its botulism antitoxin contract with the Biomedical Advanced Research and Development Authority.

BARDA manages two biodefense-related stockpiling contracts that Cangene holds with the U.S. Department of Health and Human Services.

Under the newly signed contract, Cangene is required to pursue licensure from the U.S. Food and Drug Administration for use of its botulism antitoxin. The two year extension was agreed to by both parties to allow for more time to pursue licensure.

Under the modified contract, the product delivery schedule is also to be modified to better align it with licensure activities.

Under original terms of the contract, Cangene was on target to deliver 200,000 doses of its botulism antitoxin by May 2011. Under the modified contract, the product delivery schedule is extended out to May 2013. Deliveries will be spread evenly over the next three contract years. Cangene has already delivered approximately half of the contracted doses to date.

Cangene is one of Canada's largest biopharmaceutical companies. Founded in 1984 and headquartered in Winnipeg, Manitoba, Cangene employs approximately 700 employees in eight locations across North America. Cangene operates three large manufacturing facilities - one in Baltimore and two in Winnipeg - to produce its own products and undertake contract manufacturing.